May 05, 2023
3 min watch
Save
VIDEO: Positive outcomes reported for Brimochol PF in presbyopia trial
Issue: June 25, 2023
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
Key takeaways:
- Brimochol met the primary endpoints in the U.S., the U.K. and Europe.
- About half of subjects treated with Brimochol improved from moderate to mild presbyopia at hour 10.
SAN DIEGO — In this Healio Video Perspective from Eyecelerator@ASCRS, Ben Bergo gives an overview of the positive topline phase 3 results for the Brimochol PF eye drop for the treatment of presbyopia.
“The key goal of this study really was to demonstrate a contribution of elements — that is, that Brimochol could be shown to be statistically superior to both of its two active ingredients, carbachol and brimonidine,” he said. “This paves the way for the first combination drug in this presbyopia-correcting drop category.”
Published by:
Sources/Disclosures
Collapse
Source:
Breakout and break it down: Marketplace company showcases. Presented at: Eyecelerator; May 4, 2023; San Diego.
Disclosures:
Bergo reports being the co-founder and CEO of Visus Therapeutics.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.